Searchable abstracts of presentations at key conferences in endocrinology

ea0070ep372 | Pituitary and Neuroendocrinology | ECE2020

Pasireotide therapy in a patient with pituitary macroadenoma and asymptomatic acromegaly resistant to first generation somatostatin analogues

Concepción Terroba-Larumbe María , Palacio-Mures Jose Maria , Crespo-Soto Cristina , Ventosa-Viña Marta , Cuellar-Olmedo Luis , Acuña-Garcia Manuel , Anacabe-Goyogana Itziar , Areli Ticona-Spinoza Danay , Maria Delgado-Sanz Jose , Angel Rodriguez Garcia Javier

Introduction: Acromegaly increases morbidity and mortality and should be treated even in the asymptomatic phase. It is almost always caused by a GH-producing pituitary adenoma and although transsphenoidal surgery is the treatment of choice in most cases, in others, primary medical therapy is indicated.Clinical case: A 36-year-old female with a family history of thyroid functional pathology and diagnosed with micronodular goiter was evaluated in February ...